Neurofibromatosis type 1 (NF1), a common inherited disorder, causes skin-pigmentation and CNS abnormalities, and increases the risk of developing several types of cancer. It varies widely in clinical presentation, even in family members carrying an identical mutation at the NF1 locus, suggesting genetic or environmental modifiers. To probe underlying mechanisms, Shin, Padmanabhan et al. studied the zebrafish homologues of human NF1 – nf1a and nf1b – and used targeted approaches to create nf1-null zebrafish, which showed melanophore defects and a range of CNS abnormalities at the larval stage. As hypothesised for human NF1, zebrafish nf1 genes also act as tumour suppressors: nf1-null larvae showed hyperactivation of Ras in the spinal cord, and combined loss of nf1 and p53 accelerated tumorigenesis. These data indicate that zebrafish nf1a and nf1b are tumour suppressors with crucial roles in CNS development. This is also the first animal model of NF1 in which pigmentation defects – an important feature of the human disease – have been documented. Page 881
Zebrafish model of neurofibromatosis type 1
Zebrafish model of neurofibromatosis type 1. Dis Model Mech 1 November 2012; 5 (6): 707. doi:
Download citation file:
Advertisement
Cited by
New Special Issue: Translating Multiscale Research in Rare Disease. Edited by Monica Justice, Monkol Lek, Karen Liu and Kate Rauen.
This special issue features original Research, Resources & Methods and Review-type articles that aim to interrogate the mechanisms of rare diseases to foster meaningful clinical progress in their diagnosis and treatment.
The role of the International Society for Stem Cell Research (ISSCR) guidelines in disease modelling
The ISSCR provides comprehensive guidelines and standards for using human stem cells in biomedical research. In this Editorial, Cody Juguilon and Joseph Wu discuss how and why these should be incorporated in disease modelling research.
Subject collection: Building advocacy into research
DMM’s series - Building advocacy into research - features interviews, ‘The Patient’s Voice’, with patients and advocates for a range of disease types, with the aim of supporting the highest quality research for the benefit of all patients affected by disease.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Biologists @ 100 - join us in Liverpool in March 2025
We are excited to invite you to a unique scientific conference, celebrating the 100-year anniversary of The Company of Biologists, and bringing together our different communities. The conference will incorporate the Spring Meetings of the BSCB and the BSDB, the JEB Symposium Sensory Perception in a Changing World and a DMM programme on antimicrobial resistance. Find out more and register your interest to join us in March 2025 in Liverpool, UK.
Other journals from
The Company of Biologists